Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 5/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376202 | 0.93 | GSK3B (0.49) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL2334773 | 0.90 | GSK3B (0.62) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL1378090 | 0.89 | GSK3B (0.53) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL6528861 | 0.89 | CDK1 (0.49) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL1376062 | 0.89 | GSK3B (0.59) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL2335033 | 0.89 | GSK3B (0.52) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL2338742 | 0.86 | GSK3B (0.57) | GSK3BCDK1CDK2EPHX2 | |
| SCHEMBL4380398 | 0.86 | GSK3B (0.62) | GSK3BCDK1CDK2EPHX2AURKB | |
| SCHEMBL2333075 | 0.84 | GSK3B (0.57) | GSK3BCDK1CDK2TRPA1FADS1 | |
| SCHEMBL2332201 | 0.84 | GSK3B (0.57) | GSK3BCDK1CDK2FADS1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572200-B1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-08-17 | — | — | EP | claimed |
| CN-101979382-A | Aminoindazole derivatives and use thereof as kinase inhibitors | AVENTIS PHARMA SA | 2011-02-23 | — | — | CN | claimed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | claimed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | claimed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | claimed |
| CN-1713909-A | Aminoindazole derivatives and their use as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-12-28 | — | — | CN | claimed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | claimed |
| EP-1572200-B1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-08-17 | — | — | EP | disclosed |
| CN-101979382-A | Aminoindazole derivatives and use thereof as kinase inhibitors | AVENTIS PHARMA SA | 2011-02-23 | — | — | CN | disclosed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7407981-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7196109-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | disclosed |
| CN-1713909-A | Aminoindazole derivatives and their use as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-12-28 | — | — | CN | disclosed |
| EP-1572200-A1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004062662-A1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | WO | disclosed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | OXSR1, CBR1, OXER1 | GSK3B 159/4885CDK1 63/4885CDK2 549/4885 |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | SIGMAR1, CYP2C8, CNR1 | GSK3B 3595/4885CDK1 2123/4885CDK2 2237/4885 |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.